


Name of Policy: Room Assignments for Patients Undergoing Administration of Intravenous Chemotherapeutic Agents			
Policy Number: 3364-100-01-14		Effective date: 4/8/2025	
Approving Officer: Chief Executive Officer, Chief of Staff		Original effective date: 05/24/2004	
Responsible Agent: Chief Nursing Officer			
Scope: University of Toledo Medical Center and Medical Staff			
Key words: Room Assignments, Intravenous Chemotherapeutic Agents, Administration, Biotherapy			
<input type="checkbox"/>	New policy proposal	<input type="checkbox"/>	Minor/technical revision of existing policy
<input type="checkbox"/>	Major revision of existing policy	<input checked="" type="checkbox"/>	Reaffirmation of existing policy

(A) Policy Statement

Patients undergoing the administration of intravenous chemotherapeutic and/or biotherapy agents shall be admitted to the nursing unit 4CD. This location may be changed upon the medical decision of the attending physician, if the patient requires the service intensity of an Intermediate Care or Intensive Care Unit.

(B) Purpose of policy

To provide the safest environment possible for patients, health care workers and visitors.

(C) Procedure

1. If administration of intravenous chemotherapy is planned during a patient’s hospitalization, the patient must be admitted to a room on 4CD per admission orders of a licensed physician unless the patient requires placement in an Intermediate Care or Intensive Care Unit.
2. The Admitting Office shall be notified of need for a 4CD bed preferably thirty-six hours in advance of the anticipated admission.
3. If the administration of intravenous chemotherapy is decided upon after admission and the patient is not already on 4CD, the attending physician shall request a room transfer to 4CD, unless the patient requires placement in an Intermediate Care or Intensive Care Unit based on admission criteria for these areas.

4. If the patient is in an Intensive Care unit or Intermediate Care Unit and requires the administration of intravenous chemotherapy, the Nursing Office should be notified so that an appropriate chemotherapy competent nurse can be assigned to provide this care.
5. Nursing staff on 4CD receive specific training and education on the administration of chemotherapy and biologic response modifiers. They maintain competency through regular administration of the agents, peer review, and continuing education.

<p>Approved by:</p> <p>/s/</p> <hr/> <p>Daniel Barbee Chief Executive Officer</p> <p>4/1/2025</p> <hr/> <p>Date</p> <p>/s/</p> <hr/> <p>Puneet Sindhvani, MD Chief of Staff</p> <p>4/8/2025</p> <hr/> <p>Date</p> <p><i>Review/Revision Completed by: Chief Nursing Officer, Nursing Director, Director, Outcome Management</i></p>	<p>Policies Superseded by This Policy: <i>7-01-14</i></p> <p>Initial effective date: 5/24/2004</p> <p>Review/Revision Date: 2/20/02 3/9/05 5/28/08 5/1/2011 5/1/2014 5/1/2017 5/1/2021 4/8/2025</p> <p>Next review date: 4/8/2028</p>
--	---